February , 2026: Oxymed, one of India’s leading home respiratory care companies, has announced the launch of two new 5 LPM home oxygen concentrators for the Indian market: Oxymed Cure and Oxymed Inteli 5 LPM. Together, these launches significantly strengthen Oxymed’s presence across both the affordable and premium segments of home oxygen therapy, reinforcing the company’s long-term vision of improving access, intelligence, and reliability in home respiratory care.
The launches also mark a clear delivery on Oxymed’s public roadmap. At its India Dealer Meet last year, the company had outlined plans to introduce a more affordable 5 LPM concentrator alongside a technologically advanced, innovation-led model. The introduction of Cure and Inteli demonstrates Oxymed’s focus on measured, planned innovation, translating long-term commitments into market-ready products rather than reactive launches.
Oxymed Inteli 5 LPM represents a major step forward in home oxygen therapy. It is India’s first home oxygen concentrator capable of automatically adjusting oxygen flow based on real-time patient SpO₂ levels. Paired with a Bluetooth-enabled pulse oximeter, the device continuously optimizes oxygen delivery, shifting home therapy from fixed manual settings to intelligent, responsive care. Designed for comfort and efficiency, Inteli operates at under 30 dB, consumes close to 150 watts of power, and weighs approximately 12 kg, making it the lightest and quietest concentrator in its category. With premium lithium-based sieve beds and a best-in-class warranty of three years or 15,000 hours, Inteli is positioned as Oxymed’s most advanced offering, expected to be priced around ₹45,000.
Speaking at the launch, Dr. Partha Bose, a leading Delhi-based pulmonologist and founder of the Saans Foundation, said he is proud to see Indian companies driving meaningful innovation in healthcare. He mentioned that Oxymed’s integration of oximetry into home oxygen therapy is such a simple yet powerful idea, combining clinical relevance with affordability, and added that such innovations are especially important in a country where home oxygen therapy is still not widely covered by insurance. Dr. Bose said he sees significant long-term potential for Oxymed in India’s evolving home-care ecosystem.
“Oxygen needs are not static—they change with activity, sleep, and disease progression. Oxymed Inteli responds to this reality by continuously monitoring oxygen levels and automatically adjusting flow in real time, shifting home oxygen therapy from delivery to intelligent management,” said Alok Garg, Managing Director, Oxymed.
Oxymed was the first brand in India to introduce a built-in Oxygen Purity Analyzer in home oxygen concentrators and, with Inteli, is now the first to bring automatic oxygen flow adjustment based on patient SpO₂ levels to the Indian home-care market.
Oxymed Cure expands access to reliable oxygen therapy in the affordable segment. Expected to be priced around ₹32,000, Cure delivers medical-grade oxygen purity while retaining Oxymed’s three-year warranty and nationwide service support. Built on the legacy of the highly successful Oxymed Mini, Cure lowers the cost of ownership without compromising on trust or core medical standards.
With this dual launch, Oxymed addresses both affordability and innovation, reinforcing its evolution from a category leader to a category shaper and setting new benchmarks in India’s home respiratory care market.
